Market research
ANIP ANI Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- 16.42
- Analyst target
- 108.375
- Dividend yield
- Not available
- Beta
- 0.46
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- US00182C1036
- Market cap
- 2B
- P/E ratio
- 16.42
- Analyst target
- 108.375
- Dividend yield
- Not available
- Beta
- 0.46
About
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ANIP discussion.
5 years, 4 months ago
ANI Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 7.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.9.
ANI Pharmaceuticals, Inc's total revenue rose by 19.4% to $57M since the same quarter in the previous year.
Its net income has increased by 24.8% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 328.3% to $-8M since the same quarter in the previous year.
Based on the above factors, ANI Pharmaceuticals, Inc gets an overall score of 4/5.